Methamphetamine abuse is common among humans with immunodeficiency virus (HIV). The HIV-1 regulatory protein TAT induces dysfunction of mesolimbic dopaminergic systems which may result in impaired reward processes and contribute to methamphetamine abuse. These studies investigated the impact of TAT expression on methamphetamine-induced locomotor sensitization, underlying changes in dopamine function and adenosine receptors in mesolimbic brain areas and neuroinflammation (microgliosis). Transgenic mice with doxycycline-induced TAT protein expression in the brain were tested for locomotor activity in response to repeated methamphetamine injections and methamphetamine challenge after a 7-day abstinence period. Dopamine function in the nucleus accumbens (Acb) was determined using high performance liquid chromatography. Expression of dopamine and/or adenosine A receptors (ADORA) in the Acb and caudate putamen (CPu) was assessed using RT-PCR and immunohistochemistry analyses. Microarrays with pathway analyses assessed dopamine and adenosine signaling in the CPu. Activity-dependent neurotransmitter switching of a reserve pool of nondopaminergic neurons to a dopaminergic phenotype in the ventral tegmental area (VTA) was determined by immunohistochemistry and quantified with stereology. TAT expression enhanced methamphetamineinduced sensitization. TAT expression alone decreased striatal dopamine (D1, D2, D4, D5) and ADORA1A receptor expression, while increasing ADORA2A receptors expression. Moreover, TAT expression combined with methamphetamine exposure was associated with increased adenosine A receptors (ADORA1A) expression and increased recruitment of dopamine neurons in the VTA. TAT expression and methamphetamine exposure induced microglia activation with the largest effect after combined exposure. Our findings suggest that dopamine-adenosine receptor interactions and reserve pool neuronal recruitment may represent potential targets to develop new treatments for methamphetamine abuse in individuals with HIV.
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Introduction
There is a high prevalence of methamphetamine abuse in HIV+ humans ranging between 40 and 60% (Rajasingham et al., 2012; Shoptaw et al., 2003) . Neurotoxic effects of methamphetamine and HIV disease on the brain are well documented (Ferris et al., 2008; Purohit et al., 2011) . However, studies on the brain adaptations that occur during early stages of methamphetamine use and HIV infection are uncommon.
Methamphetamine reward is largely mediated by the dopaminergic system in corticolimbic brain areas including the medial prefrontal cortex (mPFC), nucleus accumbens (Acb), and ventral tegmental area (VTA) (Koob and Volkow, 2010) . HIV infection has been associated with impaired dopamine function in the basal ganglia (Kumar et al., 2011) and excessive glutamatergic function in frontal lobes (Nagarajan et al., 2012 
